Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) EBIT (2020 - 2025)

Historic EBIT for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to -$35.3 million.

  • Janux Therapeutics' EBIT rose 164.89% to -$35.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$144.3 million, marking a year-over-year decrease of 6785.09%. This contributed to the annual value of -$98.8 million for FY2024, which is 3544.58% down from last year.
  • As of Q3 2025, Janux Therapeutics' EBIT stood at -$35.3 million, which was up 164.89% from -$45.1 million recorded in Q2 2025.
  • Janux Therapeutics' 5-year EBIT high stood at -$2.3 million for Q1 2021, and its period low was -$45.1 million during Q2 2025.
  • For the 5-year period, Janux Therapeutics' EBIT averaged around -$20.4 million, with its median value being -$18.0 million (2022).
  • Its EBIT has fluctuated over the past 5 years, first plummeted by 76807.32% in 2021, then surged by 3338.15% in 2024.
  • Janux Therapeutics' EBIT (Quarter) stood at -$13.5 million in 2021, then crashed by 35.4% to -$18.3 million in 2022, then increased by 11.66% to -$16.1 million in 2023, then plummeted by 79.85% to -$29.0 million in 2024, then fell by 21.46% to -$35.3 million in 2025.
  • Its last three reported values are -$35.3 million in Q3 2025, -$45.1 million for Q2 2025, and -$34.9 million during Q1 2025.